pirenzepine has been researched along with Depressive Disorder in 46 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-one patients were screened and 18 patients were enrolled in a 3-month open-label study of olanzapine for trichotillomania (diagnosis based on modified DSM-IV criteria)." | 9.10 | An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. ( Nejtek, VA; Stewart, RS, 2003) |
| "This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d)." | 9.08 | Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. ( Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD, 1998) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 6.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "We conducted a post hoc analysis of an international, multicenter, double-blind, 28-week study of 339 patients who met DSM-IV criteria for schizophrenia, schizophreniform, or schizoaffective disorder and were randomized to treatment with either olanzapine or risperidone." | 6.19 | Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? ( Andersen, SW; Tollefson, GD, 1999) |
| "Twenty-one patients were screened and 18 patients were enrolled in a 3-month open-label study of olanzapine for trichotillomania (diagnosis based on modified DSM-IV criteria)." | 5.10 | An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. ( Nejtek, VA; Stewart, RS, 2003) |
| "During up to 1 year of olanzapine therapy, either as monotherapy or in combination with lithium and/or fluoxetine, patients with bipolar disorder demonstrated significant improvement in mania and depression symptoms with a favorable safety profile." | 5.09 | Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. ( Gibson, PJ; Greaney, MG; Grundy, SL; Namjoshi, MA; Sanger, TM; Tohen, MF, 2001) |
| ", who received at least 6 weeks of add-on olanzapine treatment for psychotic mood disorders (schizoaffective disorders [bipolar and depressive type], bipolar disorders [I, II, and NOS], and major depressive disorder)." | 5.09 | Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. ( Grace, JJ; Narendran, R; Pato, MT; Pristach, CA; Valenti, AM; Young, CM, 2001) |
| "This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d)." | 5.08 | Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. ( Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD, 1998) |
| " This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays." | 4.79 | Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997) |
| "Since the prefrontal cortex (PFC) is thought to play an important role in depression and schizophrenia, we studied the effects of fluoxetine and olanzapine on PFC neurons in rats using extracellular, in vivo recordings." | 3.72 | Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. ( Gronier, BS; Rasmussen, K, 2003) |
| " Safety was assessed via adverse events, vital signs, laboratory analytes, electrocardiography, and extrapyramidal symptom measures." | 2.71 | Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. ( Andersen, SW; Corya, SA; Detke, HC; Dubé, S; Kelly, LS; Sanger, TM; Van Campen, LE; Williamson, DJ, 2003) |
| " The purpose of this study was to assess the potential for pharmacokinetic interaction between olanzapine and fluoxetine, a popular antidepressant that is a selective serotonin reuptake inhibitor." | 2.70 | Influence of fluoxetine on olanzapine pharmacokinetics. ( de Suray, JM; Gangji, D; Gossen, D; Onkelinx, C; Vandenhende, F, 2002) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 2.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "Schizophrenia is also associated with aggression directed at self and others." | 2.41 | The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. ( Keck, PE; McElroy, SL; Strakowski, SM, 2000) |
| "Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments." | 2.40 | Review of recent clinical studies with olanzapine. ( Kuntz, AJ; Tollefson, GD, 1999) |
| "Pretreatment with pirenzepine did not modify this response." | 1.27 | Pirenzepine inhibits growth hormone, but not thyrotropin response to thyrotropin-releasing hormone in patients with endogenous depression. ( Chiodera, P; Coiro, V; De Ferri, A; Delsignore, R; Gnudi, A; Govi, AM; Marchesi, C; Mosti, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.17) | 18.7374 |
| 1990's | 15 (32.61) | 18.2507 |
| 2000's | 30 (65.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stein, MB | 1 |
| Kline, NA | 1 |
| Matloff, JL | 1 |
| Stewart, RS | 1 |
| Nejtek, VA | 1 |
| Schatzberg, AF | 2 |
| Manning, JS | 1 |
| Gronier, BS | 1 |
| Rasmussen, K | 1 |
| Hoeh, N | 1 |
| Gyulai, L | 1 |
| Weintraub, D | 1 |
| Streim, J | 1 |
| Corya, SA | 1 |
| Andersen, SW | 3 |
| Detke, HC | 1 |
| Kelly, LS | 1 |
| Van Campen, LE | 1 |
| Sanger, TM | 3 |
| Williamson, DJ | 1 |
| Dubé, S | 1 |
| Tollefson, GD | 6 |
| Beasley, CM | 1 |
| Tran, PV | 2 |
| Street, JS | 1 |
| Krueger, JA | 1 |
| Tamura, RN | 1 |
| Graffeo, KA | 1 |
| Thieme, ME | 2 |
| Glazer, WM | 1 |
| Debattista, C | 1 |
| Solvason, HB | 1 |
| Belanoff, J | 1 |
| Ramos, RH | 1 |
| Budman, CL | 1 |
| Lu, Y | 1 |
| Ter Braak, GI | 1 |
| Rothschild, AJ | 1 |
| Bates, KS | 1 |
| Boehringer, KL | 1 |
| Syed, A | 1 |
| Kuntz, AJ | 1 |
| Brown, ES | 1 |
| Khan, DA | 1 |
| Suppes, T | 1 |
| Ober, SK | 1 |
| Hudak, R | 1 |
| Rusterholtz, A | 1 |
| Malhi, GS | 1 |
| Checkley, SA | 1 |
| Keck, PE | 1 |
| Strakowski, SM | 1 |
| McElroy, SL | 1 |
| Ohaeri, JU | 1 |
| Kaplan, M | 1 |
| Singh, HK | 1 |
| Markowitz, GD | 1 |
| Myers, G | 1 |
| Rigalleau, V | 1 |
| Gatta, B | 1 |
| Bonnaud, S | 1 |
| Masson, M | 1 |
| Bourgeois, ML | 1 |
| Vergnot, V | 1 |
| Gin, H | 1 |
| Nelson, LA | 1 |
| Swartz, CM | 1 |
| Shelton, RC | 1 |
| Tohen, M | 1 |
| Stahl, S | 1 |
| Gannon, KS | 1 |
| Jacobs, TG | 1 |
| Buras, WR | 1 |
| Bymaster, FP | 1 |
| Zhang, W | 1 |
| Spencer, KA | 1 |
| Feldman, PD | 1 |
| Meltzer, HY | 1 |
| Goodnick, PJ | 2 |
| König, F | 1 |
| von Hippel, C | 1 |
| Petersdorff, T | 1 |
| Neuhöffer-Weiss, M | 1 |
| Wolfersdorf, M | 1 |
| Kaschka, WP | 1 |
| Simard, M | 1 |
| van Reekum, R | 1 |
| Blanco López, W | 1 |
| Seguí Díaz, M | 1 |
| Arremberg Alarcón, J | 1 |
| Castelló Sabaté, A | 1 |
| Barrios, CA | 1 |
| Grundy, SL | 1 |
| Gibson, PJ | 1 |
| Namjoshi, MA | 1 |
| Greaney, MG | 1 |
| Tohen, MF | 1 |
| de Jong, J | 1 |
| Hoogenboom, B | 1 |
| van Troostwijk, LD | 1 |
| de Haan, L | 1 |
| Leslie, DL | 1 |
| Rosenheck, R | 1 |
| Weigmann, H | 1 |
| Gerek, S | 1 |
| Zeisig, A | 1 |
| Müller, M | 1 |
| Härtter, S | 1 |
| Hiemke, C | 1 |
| Narendran, R | 1 |
| Young, CM | 1 |
| Valenti, AM | 1 |
| Pristach, CA | 1 |
| Pato, MT | 1 |
| Grace, JJ | 1 |
| Pitchot, W | 1 |
| Ansseau, M | 1 |
| Parker, G | 2 |
| Malhi, G | 1 |
| Weimer, E | 1 |
| Braus, DF | 1 |
| Cavus, I | 1 |
| Thome, J | 1 |
| Marangell, LB | 1 |
| Johnson, CR | 1 |
| Kertz, B | 1 |
| Zboyan, HA | 1 |
| Martinez, JM | 1 |
| Gossen, D | 1 |
| de Suray, JM | 1 |
| Vandenhende, F | 1 |
| Onkelinx, C | 1 |
| Gangji, D | 1 |
| Coiro, V | 1 |
| Marchesi, C | 1 |
| De Ferri, A | 1 |
| Mosti, A | 1 |
| Delsignore, R | 1 |
| Govi, AM | 1 |
| Gnudi, A | 1 |
| Chiodera, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study[NCT01399450] | Phase 4 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for pirenzepine and Depressive Disorder
| Article | Year |
|---|---|
New approaches to managing psychotic depression.
Topics: Affective Disorders, Psychotic; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinic | 2003 |
Difficult-to-treat depressions: a primary care perspective.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Com | 2003 |
Pharmacologic management of psychosis in the elderly: a critical review.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm | 2003 |
Olanzapine and the new generation of antipsychotic agents: patterns of use.
Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen | 1997 |
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Comorb | 1998 |
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; D | 1999 |
Review of recent clinical studies with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Drug Resistance; Humans; Olan | 1999 |
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; | 2000 |
Dementia with Lewy bodies in Down's syndrome.
Topics: Adolescent; Adult; Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depr | 2001 |
Use of olanzapine in non-psychotic psychiatric disorders.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Humans; Ol | 2001 |
[Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].
Topics: Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Drug Therapy, Combination; Humans; Olanz | 2002 |
14 trials available for pirenzepine and Depressive Disorder
| Article | Year |
|---|---|
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.
Topics: Antipsychotic Agents; Benzodiazepines; Combat Disorders; Depressive Disorder; Double-Blind Method; D | 2002 |
An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Depressiv | 2003 |
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.
Topics: Adult; Benzodiazepines; Depressive Disorder; Drug Administration Schedule; Drug Resistance; Drug The | 2003 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre | 1997 |
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder; Double-Blind Method; | 1998 |
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; D | 1999 |
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cluster Analysis; Cognition Disorders; Depressive Diso | 1999 |
A novel augmentation strategy for treating resistant major depression.
Topics: Ambulatory Care; Basal Ganglia Diseases; Benzodiazepines; Depressive Disorder; Double-Blind Method; | 2001 |
First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; B | 2001 |
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Double-Blind Me | 2001 |
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
Topics: Adult; Affective Disorders, Psychotic; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; | 2001 |
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.
Topics: Adult; Affect; Aged; Antipsychotic Agents; Anxiety; Benzodiazepines; Depressive Disorder; Disease Pr | 2002 |
Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.
Topics: Adult; Affective Symptoms; Aged; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Drug Ad | 2002 |
Influence of fluoxetine on olanzapine pharmacokinetics.
Topics: Adult; Antipsychotic Agents; Asthenia; Benzodiazepines; Cross-Over Studies; Depressive Disorder; Dru | 2002 |
22 other studies available for pirenzepine and Depressive Disorder
| Article | Year |
|---|---|
Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex.
Topics: Action Potentials; Animals; Benzodiazepines; Depressive Disorder; Dose-Response Relationship, Drug; | 2003 |
Treatment of psychotic depression.
Topics: Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Humans; Male; Middle Aged; Olanzapine; P | 1997 |
Emergence of koro after abrupt cessation of olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Depressive Disorder; Electr | 1998 |
[Schizophrenia and depression. Special aspects in the therapy of women].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Female; Humans; Olanzapine; P | 1998 |
[The hyperglycemic dehydration syndrome].
Topics: Adult; Antidepressive Agents; Benzodiazepines; Clomipramine; Dehydration; Depressive Disorder; Diabe | 1998 |
Olanzapine response in psychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depr | 1999 |
Treatment of corticosteroid-induced mood changes with olanzapine.
Topics: Adrenal Cortex Hormones; Adult; Antipsychotic Agents; Asthma; Benzodiazepines; Depressive Disorder; | 1999 |
Hyperglycemia and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Comorbidity; Depressive Disorder; Diabetes Mel | 1999 |
Olanzapine in the treatment of psychotic depression.
Topics: Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Humans; Olanzapine; Pirenzepine; Prospec | 1999 |
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2000 |
Atypical antipsychotics for treatment of mixed depression and anxiety.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Comorbidity; Depressive Disorder; D | 2000 |
Esotropia associated with olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Esotropia; Female; Humans; O | 2000 |
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Diabetes Mellitus; Gly | 2000 |
Melancholic symptoms during concurrent olanzapine and fluoxetine.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Depressive | 2000 |
Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Citalopram; Depressi | 2000 |
[What does olanzapine give us?].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Female; Humans; | 2001 |
Interaction of olanzapine with fluvoxamine.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Depressive D | 2001 |
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Budgets; Clozapine; Comorbidity; Depressiv | 2001 |
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Benzodiazepines; Chromatography, High Pressur | 2001 |
Addition of olanzapine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Cyclohexanol | 2001 |
Are the atypical antipsychotic drugs antidepressants?
Topics: Affect; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Depr | 2002 |
Pirenzepine inhibits growth hormone, but not thyrotropin response to thyrotropin-releasing hormone in patients with endogenous depression.
Topics: Adult; Depressive Disorder; Growth Hormone; Humans; Male; Middle Aged; Pirenzepine; Thyrotropin; Thy | 1987 |